The 12 week Phase 2 result keeps the anti TL1A candidate, which targets a specific inflammation driving protein, in a competitive ulcerative colitis drug class where clinical remission and durability questions remain open.
Spyre Therapeutics reported a 10.7-point reduction in a colon-inflammation score over 12 weeks with its experimental ulcerative colitis drug SPY002, a mid-stage result that keeps the antibody in a competitive drug race but does not yet settle whether it can outpace better-established rivals.
The result, announced Monday from a 48-patient Phase 2 induction cohort, hit the primary endpoint of reducing the Robarts Histopathology Index, or RHI, a scoring system that grades microscopic inflammation in colon biopsies. The 10.7-point drop was statistically significant against baseline (p<0.0001), and Spyre said it met all key study objectives. The company framed the magnitude as "among the highest" reductions reported in the class. That framing is the company's, not an independent ranking.
Ulcerative colitis is a chronic inflammatory bowel disease in which the colon lining becomes inflamed and ulcerated; new drug classes keep arriving because the underlying immune drivers are not fully blocked by older therapies. Anti-TL1A drugs target a protein called TL1A that helps amplify that inflammatory signaling. The question for the class is whether a histology signal translates into the clinical and endoscopic improvements that regulators and payers actually weigh.
The picture is more textured than a single number. Spyre also reported that 33% of patients reached clinical remission and 42% achieved endoscopic improvement at week 12, both secondary endpoints. A Mizuho analyst note to clients called the dataset "potentially unprecedented" in its combination of histological and clinical signals, though the note represents a single sell-side view, not a class consensus.
The dataset is small. Forty-eight patients over 12 weeks of induction is a directional signal, not a verdict on whether SPY002 works in maintenance or in a broader population. RHI is a biopsy-based score, and whether a 10.7-point delta will hold up alongside more familiar clinical measures, like Mayo endoscopic scores used in most UC trials, remains open until placebo-controlled data and longer follow-up land.
Part A of the Skyline platform trial tested a single dose level of three Spyre candidates: SPY002 (anti-TL1A), SPY001 (anti-α4β7, a gut-homing integrin target used by Takeda's established UC drug Entyvio), and SPY003 (anti-IL23, the same pathway targeted by drugs like Eli Lilly's Omvoh). Part B will test two dose levels of monotherapies and combinations. The combination thesis, pairing SPY001 and SPY002 to hit the gut from two angles, is the most ambitious part of the platform design and remains a forward-looking argument rather than a tested hypothesis.
The anti-TL1A class is crowded enough that a 48-patient readout reshapes the field only modestly. Merck's tulisokibart and several earlier-stage programs from larger companies are already in motion. What Spyre's readout does is keep the company in the conversation and give it a histology number to point to as it moves into Part B.
The next meaningful inflection points are the Part B dose-selection data, maintenance durability, the SPY001-plus-SPY002 combination readout, and any direct comparisons against tulisokibart or other TL1A rivals. For now, the company has a result that is real, directional, and small. The class will not be settled on 48 patients and 12 weeks, and Spyre has not yet shown its hand on the data most analysts and clinicians will want next.